Trump abandons drug pricing proposal that would have ended certain drug rebates

WASHINGTON — The Trump administration on Wednesday abandoned one of its signature drug-pricing efforts: a ban on many of the rebates that drug companies pay to pharmacy benefit managers under Medicare.

A White House spokesman confirmed the news to STAT after it was first reported by Axios.